Clinical Trial Update: Safety and Immunogenicity of Live Attenuated Influenza H5N2 [Phase 2]

View source ↗

Summary

Phase 2 trial update on safety and immunogenicity of a live attenuated influenza vaccine for H5N2, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Due to Influenza Virus Subtype H5n2

Drugs mentioned

• Live attenuated influenza vaccine (H5N2)

Snippet

Sponsor: Mahidol University | Conditions: Influenza Due to Influenza A Virus Subtype H5N2 | Phase 2 | Status: COMPLETED